Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Chilvers

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Vaccine|August 5, 2017
Adverse events following live-attenuated intranasal influenza vaccination of children with cystic fibrosis: Results from two influenza seasonsConstantina Boikos, Lawrence Joseph, David Scheifele, et al.
Human Vaccines & Immunotherapeutics|March 9, 2017
Viral interference and the live-attenuated intranasal influenza vaccine: Results from a pediatric cohort with cystic fibrosisConstantina Boikos, Jesse Papenburg, Christine Martineau, et al.
The Lancet. Respiratory Medicine|May 9, 2021
Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension studyJordana E Hoppe, Mark Chilvers, Felix Ratjen, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 19, 2015
Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patientsValerie J Waters, Sanja Stanojevic, Nicole Sonneveld, et al.
Vaccine|November 11, 2025
Cost-effectiveness of infant and maternal RSV immunization strategies, in British Columbia, CanadaJavad Taleshi, Marina Viñeta Paramo, Allison Watts, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 5, 2019
An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB)Margaret Rosenfeld, Steve Cunningham, William T Harris, et al.
The European Respiratory Journal|April 10, 2025
Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous for <i>F508del</i> and a minimal function mutation: Results from a 96-week open-label extension studyMarcus A Mall, Claire E Wainwright, Julian Legg, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 9, 2020
Factors influencing clinical trial participation for adult and pediatric patients with cystic fibrosisMarissa Lee, Xun Yang Hu, Sameer Desai, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 30, 2019
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosisSeth Walker, Patrick Flume, John McNamara, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 22, 2022
A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variantGregory S Sawicki, Mark Chilvers, John McNamara, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Vaccine|August 5, 2017
Adverse events following live-attenuated intranasal influenza vaccination of children with cystic fibrosis: Results from two influenza seasonsConstantina Boikos, Lawrence Joseph, David Scheifele, et al.
Human Vaccines & Immunotherapeutics|March 9, 2017
Viral interference and the live-attenuated intranasal influenza vaccine: Results from a pediatric cohort with cystic fibrosisConstantina Boikos, Jesse Papenburg, Christine Martineau, et al.
The Lancet. Respiratory Medicine|May 9, 2021
Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension studyJordana E Hoppe, Mark Chilvers, Felix Ratjen, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 19, 2015
Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patientsValerie J Waters, Sanja Stanojevic, Nicole Sonneveld, et al.
Vaccine|November 11, 2025
Cost-effectiveness of infant and maternal RSV immunization strategies, in British Columbia, CanadaJavad Taleshi, Marina Viñeta Paramo, Allison Watts, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 5, 2019
An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB)Margaret Rosenfeld, Steve Cunningham, William T Harris, et al.
The European Respiratory Journal|April 10, 2025
Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous for <i>F508del</i> and a minimal function mutation: Results from a 96-week open-label extension studyMarcus A Mall, Claire E Wainwright, Julian Legg, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 9, 2020
Factors influencing clinical trial participation for adult and pediatric patients with cystic fibrosisMarissa Lee, Xun Yang Hu, Sameer Desai, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 30, 2019
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosisSeth Walker, Patrick Flume, John McNamara, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 22, 2022
A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variantGregory S Sawicki, Mark Chilvers, John McNamara, et al.
Pageof 3